Engineering efficient retinal pigment epithelium differentiation from human pluripotent stem cells.

Area of Science:

• Stem cell biology
• Ophthalmology
• Regenerative medicine

Background:

• Human embryonic stem cells (hESCs) offer potential for treating blindness by differentiating into retinal pigment epithelium (RPE) cells.
• Current hESC differentiation into RPE cells is inconsistent, hindering large-scale therapeutic applications for conditions like age-related macular degeneration.

Purpose of the Study:

• To identify and quantify sources of variability in hESC-RPE differentiation.
• To develop methods for reducing variability and improving RPE cell yield for cell therapy.

Main Methods:

• Monitoring pigmented cell emergence over time to analyze effects of cell line, passaging, and seeding density.
• Implementing feeder-free, density-controlled conditions with single-cell dissociation and seeding.
• Testing small molecule efficacy (dorsomorphin) on RPE differentiation in different hESC lines.

Main Results:

• Cell line, passaging method, passage number, and seeding density significantly impact RPE yield.
• Feeder-free, density-controlled conditions with single-cell seeding improve scalability.
• Dorsomorphin's effect on RPE differentiation varied by cell line, enhancing it in one and reducing it in another.

Conclusions:

• hESC-RPE differentiation variability can be quantified and mitigated through optimized culture conditions.
• Tailoring differentiation protocols to individual hESC line characteristics is essential for reproducible RPE production.
• Standardized protocols are necessary for the clinical translation of hESC-derived RPE cell therapies.